Pharmafile Logo
Pharmafocus logo
Advanced Search

MSD

Showing 15 posts of 243 posts found.

european_commission_web

MSD’s cancer therapy KEYTRUDA gets EU approval

January 26, 2021
Manufacturing and Production Cancer, MSD

MSD, known as Merck in the US and Canada, has received approval from the European Commission (EC) for its anti-PD-1 …

News
merckincweb

MSD discontinues development of COVID-19 vaccines

January 26, 2021
Manufacturing and Production MSD, Merck

Merck, known as MSD outside of the US and Canada, has announced that the company is discontinuing development of its …

News
moderna

MSD cashes in on Moderna investment as FDA mulls COVID-19 vaccine approval

December 4, 2020
Medical Communications, Sales and Marketing MSD, Moderna

Moderna has wrestled its way to the forefront of the industry amidst the COVID-19 pandemic, becoming one of its most …

News
merck-keytruda

NICE recommends MSD’s Keytruda for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma

October 22, 2020
Sales and Marketing MSD, NCIE, NHS, keytruda

NICE has moved to recommend the use of MSD’s blockbuster immunotherapy drug Keytruda (pembrolizumab) as a monotherapy in the treatment …

News
merckincweb

Positive five-year Keytruda survival data revealed at ESMO in metastatic, PD-L1+ non-small cell lung cancer

September 22, 2020
Manufacturing and Production, Research and Development ESMO 2020, MSD, keytruda, pharma

MSD took the opportunity at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 to unveil new Phase 3 …

News
shutterstock_38078521

New Lenvima/Keytruda combo data in a range of cancers presented at ESMO 2020

September 21, 2020
Research and Development, Sales and Marketing Cancer, ESMO2020, Eisai, Lenvima, MSD, keytruda

New data from two studies investigating the combination of Eisai’s multiple receptor tyrosine kinase inhibitor Lenvima (lenvatinib) and MSD’s blockbuster …

News
shutter

MSD partners up with Seattle Genetics in two oncology development deals potentially worth over $4bn

September 15, 2020
Manufacturing and Production, Sales and Marketing MSD, Seattle Genetics, deal, pharma

MSD has signed two new oncology-based deals with Seattle Genetics which together could be worth up to around $4.4 billion. …

News
merckincweb2

MSD unveils plans for $1.3bn central London research centre

August 19, 2020
Manufacturing and Production, Research and Development London, MSD, pharma

MSD has lifted the lid on plans to build a $1.3 billion research centre in central London.The London Discovery Research …

News
fda

FDA grants fast review for Bayer and MSD’s heart failure drug vericiguat

July 17, 2020
Medical Communications Bayer, FDA, MSD

The FDA has granted a fast Priority Review for Bayer and MSD’s heart failure drug vericiguat. This was based on …

News
european_commission_web

European green light for Lynparza in germline BRCA-mutated metastatic pancreatic cancer

July 8, 2020
Research and Development, Sales and Marketing AstraZeneca, Cancer, Europe, MSD, lynparza

The European Commission has awarded approval to AstraZeneca and MSD’s Lynparza (olaparib) for germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer, with …

News
lynparza

Lynparza secures CHMP recommendation in first-line BRCA-mutated metastatic pancreatic cancer

June 1, 2020
Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza

Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has just secured recommendation for approval from the European Medicines …

News
fda2outsideweb

Lynparza combo authorised in US for first-line maintenance of HRD-positive advanced ovarian cancer

May 11, 2020
Sales and Marketing AstraZeneca, Cancer, MSD, lynparza, ovarian cancer

Lynparza (olaparib), developed by AstraZeneca and MSD, has secured FDA approval when paired with bevacizumab as a first-line maintenance treatment …

News
merckwindow_web

MSD’s Keytruda hits Phase 3 main goal in first-line colorectal cancer sub-population

April 3, 2020
Medical Communications, Research and Development MSD, colorectal cancer, keytruda, pharma

MSD has lifted the veil on new Phase 3 for its blockbuster immunotherapy Keytruda, showing that the anti-PD-1 therapy met …

News
merck-keytruda

Keytruda rejected for NHS use for bladder cancer, will be removed from the Cancer Drugs Fund

March 12, 2020
Sales and Marketing Cancer, Kidney cancer, MSD, NHS, NICE, blader cancer, keytruda, pharma

MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has been knocked back by NICE for use on the NHS as a treatment for …

News
merckincweb

New Keytruda dosing schedule rejected in six cancers by the FDA

February 20, 2020
Sales and Marketing Cancer, FDA, MSD, keytruda, pharma

MSD’s blockbuster immunotherapy Keytruda has been stopped in its tracks by the FDA after the US regulator rejected its application …

News

Latest content

GSK’s Jemperli approved in EU as treatment for endometrial cancer

December 11, 2023

Daiichi Sankyo shares results for Ezharmia as lymphoma treatment

December 11, 2023

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023